Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$30,000.00
Jul 1, 2026
For-profit organization
YOUTH - Peptide Biochemistry Support for Partnered Discovery Programs
1044393
Experimental workflows required to advance and validate peptide candidates, generate biochemical data, and meet defined project milestones. Specific focus on peptide handling, biochemical assays, and data generation to support ongoing external collaborations.
$30,000.00
Sep 1, 2025
For-profit organization
YOUTH - Preclinical Evaluation of an mRNA-LNP Delivered SMYD3 Peptide Therapeutic in a Small Cell Lung Cancer Model
1034846
Pre-clinical proof-of-concept studies to assess therapeutic activity in an mRNA-LNP Delivered SMYD3 Peptide Therapeutic both patient-derived cell lines and a murine xenograft model of SCLC. Conduct in vitro screening (viability, proliferation, and apoptosis assays), and in vivo xenograft monitoring. Collect and analyze experimental data; contribute to technical reports and data summaries for internal review and patent support.
$30,000.00
Sep 1, 2024
For-profit organization
Development of drug-discovery platform
1022292
Completion of pharmacokinetic (PK) and pharmacodynamics (PD) studies to provide essential data on how a target drug candidate is processed and delivered to the lung and assessing therapeutic effects.